Cobimetinib

Cobimetinib is a selective MEK1/2 inhibitor used in combination with vemurafenib for the treatment of BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma. It blocks the MEK-ERK signaling pathway downstream of mutant BRAF, enhancing antitumor activity. Mediocon Inc supplies pharmaceutical-grade Cobimetinib meeting IP/BP/EP/USP standards.

Key Features

• Selective MEK1/2 kinase inhibitor
• IP/BP/EP/USP compliant, Assay 99.0% Min.
• Used in BRAF-mutant melanoma combination therapy
• Suitable for oral tablet formulations

Applications

• BRAF V600E/K mutant melanoma treatment
• Combination with BRAF inhibitors
• Oncology oral tablet manufacturing
• Clinical research and trial supplies

Why Choose Mediocon

• ISO 9001:2015 & GMP certified manufacturing
• Consistent batch-to-batch quality with full CoA
• Export-ready documentation: COO, MSDS, DMF
• Flexible MOQ for both R&D and commercial scale
• Dedicated QA support for regulatory filings